Last reviewed · How we verify
Neoadjuvant letrozole (postmenopausal women) (neoadjuvant-letrozole-postmenopausal-women)
Neoadjuvant letrozole (postmenopausal women) (generic name: neoadjuvant-letrozole-postmenopausal-women) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | neoadjuvant-letrozole-postmenopausal-women |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Hyperglycaemia
- Nausea
- Fatigue
- Rash
- Stomatitis
- Decreased appetite
- Headache
- Alopecia
- Asthenia
- Vomiting
- Hot flush
Key clinical trials
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (PHASE2)
- Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer. (PHASE2)
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PHASE2)
- Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause (PHASE2)
- Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer (PHASE3)
- Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant letrozole (postmenopausal women) CI brief — competitive landscape report
- Neoadjuvant letrozole (postmenopausal women) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Neoadjuvant letrozole (postmenopausal women)
What is Neoadjuvant letrozole (postmenopausal women)?
Neoadjuvant letrozole (postmenopausal women) (neoadjuvant-letrozole-postmenopausal-women) is a pharmaceutical drug developed by Pfizer Inc..
Who makes Neoadjuvant letrozole (postmenopausal women)?
Neoadjuvant letrozole (postmenopausal women) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Neoadjuvant letrozole (postmenopausal women)?
neoadjuvant-letrozole-postmenopausal-women is the generic (nonproprietary) name of Neoadjuvant letrozole (postmenopausal women).
What development phase is Neoadjuvant letrozole (postmenopausal women) in?
Neoadjuvant letrozole (postmenopausal women) is in Phase 2.
What are the side effects of Neoadjuvant letrozole (postmenopausal women)?
Common side effects of Neoadjuvant letrozole (postmenopausal women) include Diarrhoea, Hyperglycaemia, Nausea, Fatigue, Rash, Stomatitis.